Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Neuro-Oncology and Neurosurgical Oncology

CDK1-Driven Phosphorylation Networks Promote Glioblastoma Progression via MAP1B-Mediated Microtubule Destabilization

Provisionally accepted
Jun-Tao  LiJun-Tao Li1Meng-Da  LiMeng-Da Li2Zhi-Xiao  LiZhi-Xiao Li1Yongji  GuoYongji Guo2Rong-Jun  QianRong-Jun Qian1,3,4*Chunxiao  MaChunxiao Ma1,2,4*
  • 1Henan Provincial People's Hospital, Zhengzhou, China
  • 2Henan University People's Hospital, zheng zhou, China
  • 3People's Hospital of Henan University, zheng zhou, China
  • 4People's Hospital of Zhengzhou University, zheng zhou, China

The final, formatted version of the article will be published soon.

Background Glioblastoma (GBM) is the most aggressive and prevalent malignant brain tumor in adults, with poor prognosis despite current therapies. Cyclin-dependent kinase 1 (CDK1), a master regulator of cell cycle progression, has been implicated in oncogenesis, but its downstream phosphorylation network in GBM remains incompletely defined. Methods CDK1 expression was examined in clinical GBM tissues and cell lines. Functional studies were performed in U251 cells using CDK1-specific shRNAs. Label-free phosphoproteomic profiling and bioinformatics analyses were conducted to map CDK1-regulated signaling pathways and substrates. Prognostic associations were evaluated using Clinical Proteomic Tumor Analysis Consortium (CPTAC) datasets, and functional assays were used to validate candidate substrates. Results CDK1 was significantly upregulated in GBM tissues, and its knockdown suppressed proliferation, migration, and invasion of U251 cells. Phosphoproteomic analysis identified 15,156 phosphorylation sites, of which 2,836 were significantly altered by CDK1 inhibition, implicating pathways related to cell cycle regulation, DNA replication, and DNA damage repair. Subcellular localization revealed nuclear enrichment, including phosphorylation changes in RB1 and TP53. Importantly, CDK1-mediated hyperphosphorylation of microtubule-associated protein 1B (MAP1B) at multiple residues (Ser832, Ser1260, Ser1899, Ser1939, Ser2209, Ser2271) correlated with poor prognosis and promoted microtubule destabilization. Functional assays confirmed that MAP1B knockdown impaired GBM cell growth, migration, and invasion. Conclusion This study demonstrates that CDK1 is a critical oncogenic driver in GBM, regulating broad phosphosignaling networks and promoting tumor progression via MAP1B-dependent microtubule destabilization. MAP1B phosphorylation emerges as a potential prognostic biomarker. These findings support the development of CDK1-targeted therapies, alone or combined with microtubule-stabilizing agents, for improved GBM management.

Keywords: Cdk1, GBM, MAP1B, microtubule, Phosphorylation

Received: 13 Jun 2025; Accepted: 16 Dec 2025.

Copyright: © 2025 Li, Li, Li, Guo, Qian and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Rong-Jun Qian
Chunxiao Ma

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.